Search Patents
  • 97316, a human amine oxidase family member and uses therefor
    Publication number: 20040005685
    Abstract: The invention provides isolated nucleic acids molecules, designated 97316 nucleic acid molecules, which encode novel amine oxidase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 97316 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 97316 gene has been introduced or disrupted. The invention still further provides isolated 97316 proteins, fusion proteins, antigenic peptides and anti-97316 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 3, 2003
    Publication date: January 8, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Peter J. Olandt, Mark J. Williamson
  • Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
    Publication number: 20090203122
    Abstract: Cloning, expression, viral and delivery vectors and hosts which contain nucleic acid coding for at least one peripheral nervous system specific (PNS) sodium channel peptide (SCP), isolated PNS SCP, and compounds and compositions and methods, are provided, for isolating, crystallizing, x-ray analysing molecular modeling, rational drug designing, selecting, making and using therapeutic or diagnostic agents or ligands having at least one peripheral nervous system specific (PNS) sodium channel (SC) modulating activity.
    Type: Application
    Filed: June 6, 2007
    Publication date: August 13, 2009
    Applicant: The Research Foundation of State University of New York
    Inventors: Gail Mandel, Simon Halegoua
  • GLYCOPEPTIDES AND METHODS OF MAKING AND USING THEM
    Publication number: 20110045046
    Abstract: In one embodiment, the invention provides glycopeptides (or carbohydrate-peptide conjugates) comprising TACAs that direct against (e.g., bind specifically to) cytotoxic T lymphocytes (CTLs) or helper T cells for, e.g., CTL- or T-helper-based immunotherapy of carcinomas, and methods for making and using the glycopeptides of the invention. In one embodiment, the invention provides novel glycopeptides comprising tumor-derived carbohydrate or tumor-derived epitopes that specifically bind to major histocompatibility (MHC) class I molecules on cytotoxic T lymphocytes (CTLs) or MHC molecules on helper T cells, and methods for using same, e.g., as a vaccine, including a pan-cancer vaccine.
    Type: Application
    Filed: February 26, 2009
    Publication date: February 24, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Alessandra Franco
  • 24554, a human ubiquitin carboxyl-terminal hydrolase family member and uses therefor
    Publication number: 20030082785
    Abstract: The invention provides isolated nucleic acids molecules, designated 24554 nucleic acid molecules, which encode novel ubiquitin carboxy-terminal hydrolase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 24554 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 24554 gene has been introduced or disrupted. The invention still further provides isolated 24554 proteins, fusion proteins, antigenic peptides and anti-24554 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: October 11, 2002
    Publication date: May 1, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rosana K. Libermann, Heidi Lynn Spurling
  • 32620, a novel human sodium-sugar symporter family member and uses thereof
    Publication number: 20020156002
    Abstract: The invention provides isolated nucleic acids molecules, designated 32620 nucleic acid molecules, which encode novel sodium-sugar symporter members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32620 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32620 gene has been introduced or disrupted. The invention still further provides isolated 32620 proteins, fusion proteins, antigenic peptides and anti-32620 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: August 13, 2001
    Publication date: October 24, 2002
    Inventors: Rory A.J. Curtis, Inmaculada Silos-Santiago
  • Molecular roadblocks for RpoN binding sites
    Patent number: 9392790
    Abstract: The present invention relates to, inter alia, a method for repressing transcription and/or gene expression from RpoN binding sites (or promoters) or cryptic promoters upstream of RpoN binding sites. The method comprises providing an agent that specifically and selectively binds to RpoN promoter sequences to inhibit or repress the expression of genes downstream of that promoter; and contacting the RpoN promoter with the agent. Agents for repressing transcription and/or gene expression from RpoN promoters are also provided. The agent can be a composition that binds specifically to the ?24, ?12, or ?24/?12 site(s) for RpoN promoter interference. Synthetic peptides, vectors, and host cells are also provided.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: July 19, 2016
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Christopher T. Nomura, Benjamin R. Lundgren
  • Novel leucine rich repeat-containing molecules and uses therefor
    Publication number: 20020025554
    Abstract: The invention provides isolated nucleic acids molecules, designated AZAD nucleic acid molecules, which encode novel secreted proteins containing multiple leucine rich repeats. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing AZAD nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an AZAD gene has been introduced or disrupted. The invention still further provides isolated AZAD proteins, fusion proteins, antigenic peptides and anti-AZAD antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: February 20, 2001
    Publication date: February 28, 2002
    Applicant: Millennium Pharmaceuticals, Inc. a Massachusetts Corporation
    Inventor: Mehran Mohamad Khodadoust
  • Nucleic acid sequence of senescence asssociated gene
    Patent number: 6025194
    Abstract: Human gene GC6 is expressed more abundantly in senescent cells than young cells. Isolated, purified, and recombinant nucleic acids and proteins corresponding to the human GC6 gene and its mRNA and protein products, as well as peptides and antibodies corresponding to the GC6 protein can be used to identify senescent cells, distinguish between senescent and young cells, identify agents that alter senescent gene expression generally and GC6 expression specifically; such agents as well as GC6 gene and gene products and products corresponding thereto can be used to prevent and treat diseases and conditions relating to cell senescence.
    Type: Grant
    Filed: November 19, 1997
    Date of Patent: February 15, 2000
    Assignee: Geron Corporation
    Inventor: Walter Funk
  • PCSK9 ANTAGONISTS
    Publication number: 20100068199
    Abstract: The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
    Type: Application
    Filed: September 11, 2009
    Publication date: March 18, 2010
    Inventors: Hong Liang, Yasmina Noubia Abdiche, Javier Fernando Chaparro Riggers, Bruce Charles Gomes, Julie Jia Li Hawkins, Jaume Pons, Xiayang Qiu, Pavel Strop, Yuli Wang
  • Novel molecules of the TANGO-93-related protein family and uses thereof
    Publication number: 20030059892
    Abstract: Novel TANGO-93 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length TANGO-93 proteins, the invention further provides isolated TANGO-93 fusion proteins, antigenic peptides and anti-TANGO-93 antibodies. The invention also provides TANGO-93 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a TANGO-93 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: October 9, 2002
    Publication date: March 27, 2003
    Applicant: Millennium Pharmaceuticals, Inc., a Delaware corporation
    Inventor: Yang Pan
  • OCT1p, a protein having homology to the organic and sugar transporter family of proteins, and uses thereof
    Publication number: 20040209287
    Abstract: Novel OCTlp polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length OCT-like proteins, the invention further provides isolated OCTlp fusion proteins, antigenic peptides and anti-OCTlp antibodies. The invention also provides OCTlp nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an OCTlp gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: December 19, 2003
    Publication date: October 21, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Andrew J. Goodearl, Maria Alexandra Glucksmann
  • Method for protein transfer
    Patent number: 6316256
    Abstract: Methods for transferring one or more proteins to a cell are disclosed. The protein or proteins to be transferred are in the form of a fusion protein, and contain at least one domain encoding for a protein or peptide having trans signaling and/or adhesion function. The fusion protein is transferred to a cell by binding to a lipidated protein, which has been incorporated into the cell membrane. Methods for using cells which have undergone protein transfer according to the present methods are also disclosed. This includes use in a cancer vaccine, use for treatment of cancer or autoimmune disease, and use in determining costimulator threshold levels.
    Type: Grant
    Filed: January 3, 2000
    Date of Patent: November 13, 2001
    Assignee: TR Associates, L.L.C.
    Inventors: Mark L. Tykocinski, Aoshuang Chen, Guoxing Zheng
  • Mutant Paramyxovirus and Method for Production Thereof
    Publication number: 20090269850
    Abstract: The present invention provides a modified paramyxovirus containing a reduced amount of receptor-binding protein compared with the wild type; a method of preparing a modified paramyxovirus, comprising the following steps: (1) a step for introducing a nucleic acid that suppresses the expression of a receptor-binding protein of a paramyxovirus into an animal cell, (2) a step for infecting the paramyxovirus to the cell, and (3) a step for isolating paramyxovirus particles replicated in the cell; and a modified paramyxovirus prepared by the method of preparation mentioned above.
    Type: Application
    Filed: November 24, 2006
    Publication date: October 29, 2009
    Inventors: Yasufumi Kaneda, Katsuto Tamai, Kotaro Saga, Masako Kawachi
  • Recombinant human albumin fusion proteins with long-lasting biological effects
    Patent number: 7244833
    Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: July 17, 2007
    Inventors: Zailin Yu, Yan Fu
  • Molecules of the follistatin-related protein family and uses therefor
    Patent number: 5942420
    Abstract: Novel FMCP polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length FMCP proteins, the invention further provides isolated FMCP fusion proteins, antigenic peptides and anti-FMCP antibodies. The invention also provides FMCP nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a FMCP gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: November 17, 1997
    Date of Patent: August 24, 1999
    Assignee: Millennium BioTherapeutics, Inc.
    Inventor: Douglas A. Holtzman
  • ACTR-1 a novel human acyltransferase and uses thereof
    Patent number: 7052888
    Abstract: The invention provides isolated nucleic acid molecules, designated ACTR-1 nucleic acid molecules, which encode novel acyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing ACTR-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an ACTR-1 gene has been introduced or disrupted. The invention still further provides isolated ACTR-1 proteins, fusion proteins, antigenic peptides and anti-ACTR-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: August 21, 2001
    Date of Patent: May 30, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rosana Kapeller-Libermann, Thomas Joseph Logan
  • Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (CALSARCINS)
    Publication number: 20040210950
    Abstract: The present invention relates to the polypeptides known as calcineurin associated protein (calsarcin). Calsarcins-1, -2, and -3 bind to calcineurin, telethonin, and a-actinin, which provides a link between these molecules and the sarcomere. Sarcomeric dysfunction ultimately leads to activation of calcineurin and consequent hypertrophic cardiomyopathy. Thus, methods utilizing calsarcin as it regards these medical conditions are herein provided and include screening for peptides which interact with calsarcin, screening for modulators of calsarcin binding to calcineurin or &agr;-actinin, methods to modulate calcineurin activity, methods to inhibit calcineurin activation of gene transcription and methods for treating cardiac hypertrophy, heart failure and Type II diabetes.
    Type: Application
    Filed: January 16, 2004
    Publication date: October 21, 2004
    Applicant: Board of Regents, The University of Texas System
    Inventors: Eric Olson, Norbert Frey
  • 68999, a human ubiquitin carboxyl-terminal hydrolase family member and uses therefor
    Patent number: 6900044
    Abstract: The invention provides isolated nucleic acids molecules, designated 68999 nucleic acid molecules, which encode ubiquitin carboxyl-terminal hydrolase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 68999 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 68999 gene has been introduced or disrupted. The invention still further provides isolated 68999 proteins, fusion proteins, antigenic peptides and anti-68999 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: May 31, 2005
    Assignee: Millennium Pharmaceutical, Inc.
    Inventor: Rosana Kapeller-Libermann
  • Collagen XXII, a novel human collagen and uses thereof
    Publication number: 20030143564
    Abstract: The invention provides isolated nucleic acids molecules, designated collagen XXII nucleic acid molecules, which encode a novel collagen. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing collagen XXII nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a collagen XXII gene has been introduced or disrupted. The invention still further provides isolated collagen XXII proteins, fusion proteins, antigenic peptides and anti-collagen XXII antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: July 24, 2002
    Publication date: July 31, 2003
    Inventors: Robert Eugene Burgeson, Manuel Koch, Douglas R. Keene, William Joseph Brunken, Leena Bruckner-Tuderman
  • Polynucleotides encoding mhc class i-restricted htert epitopes, analogues thereof or polyepitopes
    Publication number: 20100172878
    Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
    Type: Application
    Filed: July 31, 2006
    Publication date: July 8, 2010
    Inventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut